RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307)

Hiroshi Saeki, Tomoko Jogo, Tetsuro Kawazoe, Tomohiro Kamori, Yu Nakaji, Yoko Zaitsu, Minako Fujiwara, Yoshifumi Baba, Tetsu Nakamura, Naoki Iwata, Akinori Egashira, Tomonori Nakanoko, Masaru Morita, Yoshihiro Tanaka, Yasue Kimura, Tomotaka Shibata, Yuichiro Nakashima, Yasunori Emi, Akitaka Makiyama, Eiji OkiShoji Tokunaga, Mototsugu Shimokawa, Masaki Mori

研究成果: ジャーナルへの寄稿学術誌査読

4 被引用数 (Scopus)

抄録

Objective:The aim of this study is to identify biomarkers that predict efficacy of preoperative therapy and survival for esophageal squamous cell carcinoma (ESCC).Background:It is essential to improve the accuracy of preoperative molecular diagnostics to identify specific patients who will benefit from the treatment; thus, this issue should be resolved with a large-cohort, retrospective observational study.Methods:A total of 656 patients with ESCC who received surgery after preoperative CDDP + 5-FU therapy, docetaxel + CDDP + 5-FU therapy or chemoradiotherapy (CRT) were enrolled. Immunohistochemical analysis of TP53, CDKN1A, RAD51, MutT-homolog 1, and programmed death-ligand 1 was performed with biopsy samples obtained before preoperative therapy, and expression was measured by immunohistochemistry.Results:In all therapy groups, overall survival was statistically separated by pathological effect (grade 3 > grade 2 > grade 0, 1, P < 0.0001). There was no correlation between TP53, CDKN1A, MutT-homolog 1, programmed death-ligand 1 expression, and pathological effect, whereas the proportion of positive RAD51 expression (≥50%) in cases with grade 3 was lower than that with grade 0, 1, and 2 (P = 0.022). In the CRT group, the survival of patients with RAD51-positive tumor was significantly worse than RAD51-negative expressors (P = 0.0119). Subgroup analysis of overall survival with respect to positive RAD51 expression indicated preoperative chemotherapy (CDDP + 5-FU or docetaxel + CDDP + 5-FU) was superior to CRT.Conclusions:In ESCC, positive RAD51 expression was identified as a useful biomarker to predict resistance to preoperative therapy and poor prognosis in patients who received preoperative CRT. Administration of preoperative chemotherapy may be warranted for patients with positive RAD51 expression.

本文言語英語
ページ(範囲)692-699
ページ数8
ジャーナルAnnals of surgery
275
4
DOI
出版ステータス出版済み - 4月 1 2022

!!!All Science Journal Classification (ASJC) codes

  • 外科

フィンガープリント

「RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル